AGXT and allergic disease: Only 51.4% of participants with positive SPT and/or sIgE to shrimp had a dose-limiting reaction at or below 300 mg of shrimp during DBPCFCs, therefore SPT and sIgE are currently insufficient as a pre-screening tool for shrimp allergy clinical trials.